ArticleScientific reports2026
Tenoxicam-loaded bioglass/chitosan composites for bone tissue engineering: in vitro characterization, sustained drug release, and antimicrobial activity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of multifunctional biomaterials that combine structural support with therapeutic functions is a key challenge in bone tissue engineering. Bioglass and chitosan are widely studied for their bioactivity and biocompatibility, while non-steroidal anti-inflammatory drugs (NSAIDs) such as Tenoxicam provide pain relief and inflammation control. We synthesized novel Tenoxicam-loaded Bioglass/Chitosan (TXC/BG/Cs) composites via the sol–gel process, incorporating 1, 2, and 3 wt% drug concentrations. The composites were characterized by FTIR, XRD, SEM, and EDX before and after immersion in simulated body fluid (SBF) to evaluate physicochemical properties and bioactivity. Sustained drug release was monitored for 33 days using UV–Vis spectroscopy. Antibacterial activity was assessed against Gram-positive (Staphylococcus aureus, S. haemolyticus) and Gram-negative (Escherichia coli, Klebsiella pneumoniae) bacteria using the agar well diffusion method. FTIR and XRD confirmed the formation of hydroxyapatite layers on composite surfaces after immersion in SBF, indicating strong bioactivity. SEM revealed a porous microstructure favorable for osteointegration, while EDX confirmed increased Ca and P deposition. The composites exhibited sustained Tenoxicam release following zero-order kinetics, with C3 (3 wt%) showing the highest cumulative release. Antimicrobial testing demonstrated significant inhibition zones against both Gram-positive and Gram-negative strains. These findings suggest that TXC/BG/Cs composites integrate drug delivery, antibacterial functionality, and bone-bonding capability, making them promising candidates for bone tissue engineering and post-surgical implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.